Showing results (131-140 of 242) with videos related to
Sort By:
Pageof 25
Journal of Neuro-Oncology|August 10, 2012
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233Steven N Gurley, Ammaar H Abidi, Patrick Allison, et al.Cancer Research|May 19, 2005
Gene expression profiling and genetic markers in glioblastoma survivalJeremy N Rich, Christopher Hans, Beatrix Jones, et al.Neuro-Oncology|October 23, 2018
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomasBill H Diplas, Heng Liu, Rui Yang, et al.Molecular Cancer Therapeutics|September 4, 2007
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasionAnita B Hjelmeland, Kathryn P Lattimore, Brian E Fee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyVidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, et al.Journal of Neuro-Oncology|March 23, 2018
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma modelsStephen T Keir, Vidyalakshmi Chandramohan, Carlee D Hemphill, et al.Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cellsPeter E Fecci, Alison E Sweeney, Peter M Grossi, et al.BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.Cancer Research|December 4, 2012
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomasGenglin Jin, Zachary J Reitman, Christopher G Duncan, et al.Pageof 25